| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CP466722 | GDSC1000 | pan-cancer | AAC | 0.063 | 0.03 |
| mRNA | A-804598 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.03 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | 0.085 | 0.03 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.03 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.03 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.04 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | 0.076 | 0.04 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.077 | 0.04 |
| mRNA | AZD-2281 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.04 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.079 | 0.04 |